United Therapeutics

3D bioprinting of tissues and organs

Posted on Updated on

According to Yehiel Tal, the Chief Executive Officer of CollPlant, “This fund raising is intended to support the advancement of our pipeline in the fields of medical aesthetics and 3D bioprinting of tissues and organs. We are now focused on facilitating our development programs of dermal fillers and regenerative breast implants. Our collaboration with United Therapeutics, which is using our BioInk technology for 3D printing lungs, is progressing, and we continue to expand our business collaborations with large international healthcare companies that seek to implement our revolutionary regenerative medicine technology. We are very pleased to have entered into this transaction with Mr. Sagi and the other investors.”

 

CollPlant Biotechnologies Raising $5.5 Million

Advertisements